Previous 10 | Next 10 |
The following slide deck was published by Recro Pharma, Inc. in conjunction with this event. For further details see: Recro Pharma Investor Presentation - Slideshow
Recro Pharma ([[REPH]] +15.5%) is high post Q1 results beat, with revenue of $16.8M (-22.9% Y/Y); and net loss of $6.76M, reduced from $7.69M a year ago.Company says the decline in revenue was primarily the result of the discontinuation of two commercial product lines by commercial partners a...
Recro Pharma (REPH): Q1 GAAP EPS of -$0.23 beats by $0.03.Revenue of $16.8M (-22.9% Y/Y) beats by $0.37M.For the full year 2021, the company expects revenue to be approximately $68 to $72 million ($70.96M consensus), EBITDA, as adjusted* to be in the range of $15 to $17 million, and net loss ...
Revenues of $16.8 Million Represent an Increase of 70% Compared to Q4 2020 Revenue Multiple New Business Agreements Signed Facilities Expansion and Enhancements Continue Company to Host Conference Call Today at 4:30 p.m. ET EXTON, Pa., May 06, 2021 (GLOBE N...
MALVERN, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug prod...
GAINESVILLE, Ga., April 15, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug ...
MALVERN, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug prod...
Six Recent Hires Provide Broader Coverage and Expanded Capabilities in the Areas of Sales and Marketing Significant Traction Already Achieved in First Months of 2021 MALVERN, Pa., April 05, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH ),...
BXRX is a currently discounted analgesia company that suffered from reduced demand due to COVID-19 pressure on elective surgeries. The company currently has an FDA-approved post-op analgesic that is favored by anesthesiologists, as well as a focused pipeline that could push it to the ...
MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug prod...
News, Short Squeeze, Breakout and More Instantly...
Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging CoreRx to Commence a Tender Offer for all Outstanding Shares of Societal CDMO, Inc. CLEARWATE...
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets Complementary Capabilities Range from API Manufacturing through Process Development and cGMP Manufacturing to Fill/Finish GAINESVILLE, Ga. ...
Recorded Q3 Revenue of $23.6 Million Signed Multiple New Business Agreements with New and Existing Customers Closed Public Offering Raising Gross Proceeds of Approximately $8.3 Million Initiated Corporate Restructuring; Expected to Result in Annualized Savings of Approxi...